Related Experiment Video
Updated: Jul 15, 2026
06:39
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
Published on: June 13, 2025
Laboratory Monitoring Unfractionated Heparin Treatments: Unanswered Issues.
1Hematology Department, Université Côte d'Azur, Nice University Hospital, Nice, France.
International Journal of Laboratory Hematology
|July 14, 2026
Summary
Monitoring unfractionated heparin (UFH) efficacy is crucial due to its narrow therapeutic index. Standard assays like aPTT and anti-Xa activity are widely used, but evidence-based therapeutic ranges and standardization remain limited, impacting patient care.
Area of Science:
- Pharmacology
- Clinical Chemistry
- Hematology
Background:
- Unfractionated heparin (UFH) remains a critical anticoagulant for high-risk patients despite newer alternatives.
- Its narrow therapeutic index necessitates monitoring to prevent thrombosis or hemorrhage.
- Current monitoring practices rely on limited scientific data and face standardization challenges.
Purpose of the Study:
- To review the current landscape of unfractionated heparin monitoring.
- To identify gaps in scientific evidence regarding assay selection and therapeutic ranges.
- To highlight pre-analytical variables affecting UFH assay reliability.
Main Methods:
- Review of existing literature on UFH monitoring assays.
- Analysis of commonly used plasma-based (aPTT, anti-Xa) and whole blood (ACT) assays.
- Discussion of established therapeutic ranges and their evidence base.
Main Results:
- Activated partial thromboplastin time (aPTT) and anti-Xa activity are the most prevalent plasma-based assays.
- Therapeutic ranges for aPTT (1.5-2.5x control) and anti-Xa (0.30-0.70 IU/mL) lack robust evidence.
- Assays exhibit heterogeneity in UFH sensitivity, and pre-analytical factors (tube type, fill volume, time to analysis) require standardization.
Conclusions:
- Despite decades of use, optimal biological monitoring of UFH efficacy requires further research.
- Standardization of assays and validation of therapeutic ranges are essential for safe and effective UFH therapy.
- Addressing pre-analytical variables is critical for reliable UFH monitoring.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:27Pulmonary Embolism III: Nursing Management
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...